NKTR Shares Outstanding History
Below is a table of the NKTR shares outstanding history going back to 2/26/2010:

Date NKTR Shares Outstanding
2/26/201093.65M
4/30/201094.06M
7/23/201094.19M
10/31/201094.33M
2/25/2011113.75M
4/25/2011114.07M
8/1/2011114.42M
10/31/2011114.43M
2/24/2012114.53M
4/27/2012114.61M
8/6/2012114.91M
11/5/2012115.17M
2/21/2013115.29M
4/30/2013115.52M
8/1/2013115.76M
10/31/2013116.12M
2/20/2014126.65M
4/30/2014126.98M
7/24/2014127.30M
10/30/2014128.44M
2/20/2015131.38M
4/23/2015131.53M
7/30/2015132.37M
10/29/2015133.45M
2/19/2016135.94M
4/27/2016136.26M
7/28/2016136.73M
10/27/2016152.84M
2/24/2017153.83M
5/4/2017155.15M
8/3/2017156.33M
11/2/2017157.47M
2/22/2018160.92M
5/3/2018171.40M
8/3/2018172.47M
11/1/2018173.09M
2/22/2019174.10M
5/1/2019174.31M
8/1/2019175.27M

Also see: NKTR Market Cap History
and NKTR YTD Return
NKTR Historical Shares Outstanding:
+6.87% CAGR
NKTR Historical Shares Outstanding: +6.87% CAGR

Mouse over chart for data details
2/26/2010 ...8/1/2019
Nektar Therapeutics is a research-based biopharmaceutical company. Co.'s proprietary drugs and drug candidates that have either received regulatory approval or are being developed by Co. or in collaboration with other pharmaceutical companies or independent investigators include: ONZEALD™, a topoisomerase I inhibitor targeted for advanced metastatic breast cancer in patients with brain metastases; NKTR-181, an orally-available mu-opioid analgesic molecule for moderate to severe chronic pain; NKTR-214, a CD122-biased immune-stimulatory cytokine targeted for oncology; NKTR-358 for autoimmune disease; NKTR-262 targeted for solid tumors; and NKTR-255 targeted for immuno-oncology. We show 39 historical shares outstanding datapoints in our coverage of NKTR's shares outstanding history.

Understanding the changing numbers of NKTR shares outstanding — and comprehending the concept of differing number of shares outstanding in general comparing companies like NKTR versus peers — is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies. Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history. With this page we aim to empower investors researching NKTR by allowing them to research NKTR shares outstanding history as well as any other stock in our coverage universe.
Quotes delayed 20 minutes
Get Free SEC filing alerts for NKTR:
NKTR SEC Filing Email Alerts ServiceExternal link
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: Shares Outstanding Importance


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Nektar Therapeutics (NKTR) is categorized under the Healthcare sector; to help you further research historical shares outstanding numbers, below are some other companies in the same sector:

NLNK Shares Outstanding History
NOVN Shares Outstanding History
NSTG Shares Outstanding History
NTLA Shares Outstanding History
NTRA Shares Outstanding History
NTRP Shares Outstanding History
NURO Shares Outstanding History
NUVA Shares Outstanding History
NVAX Shares Outstanding History
NVIV Shares Outstanding History
More Healthcare companies »

 

NKTR Shares Outstanding History | www.SharesOutstandingHistory.com | Copyright © 2017 - 2019, All Rights Reserved

Nothing in SharesOutstandingHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.